Notably, PA treatment significantly elevated IL-4 levels to 149.40% ± 12.85% (p < 0.001 vs. WT + Aβ + PA; n = 5 per group; Figure 6F) and decreased the levels of pro-inflammatory cytokines, with TNF-α reduced to 137.80% ± 23.50% (p = 0.006 vs. WT + Aβ + PA; n = 5 per group; Figure 6G) and IL-6 to 91.80% ± 7.88% (p = 0.028 vs. WT + Aβ + PA; n = 5 per group; Figure 6H), highlighting its potential therapeutic benefits in reducing inflammation in AD. This evidence concerns the gene IL4 and Alzheimer disease.